News & Research
Treating Diabetes and Coronary Artery Disease
Findings of the international Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial did not demonstrate a significant advantage of revascularization over medical therapy for diabetes patients with coronary artery disease (CAD).
The 2,368 participants in the study all had both type 2 diabetes and CAD, and they were randomized to receive either revascularization or medical therapy alone for CAD, and either insulin provision or insulin sensitization.
In an average follow-up of 5.3 years, the treatment groups demonstrated similar mortality rates, with the five-year survival rate ranging from 87.8 percent in the medical-therapy group to 88.3 percent in the revascularization group. In addition, all treatment groups had a similar proportion of patients without a major cardiovascular event.
The authors note, "The findings reinforce those of the COURAGE trial, which supported medical therapy as a reasonable initial approach in these patients."
(c)Copyright 2009 Information, Inc.
Medscape (11/06/09) Krumholz, Harlan M.
The information contained in this article does not necessarily reflect the views and opinions of the American Diabetes Association.
(c) Copyright 2010 Information, Inc.
70th Scientific Sessions
Join your colleagues at the world’s largest and most prestigious diabetes meeting.
